Pre-made Pelgifatamab benchmark antibody ( Whole mAb ADC, anti-FOLH1/GCPII therapeutic antibody, Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-434

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-434 Category Tag

Product Details

Pre-Made Pelgifatamab biosimilar, Whole mAb ADC, Anti-FOLH1/GCPII Antibody: Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Pelgifatamab biosimilar, Whole mAb ADC, Anti-FOLH1/GCPII Antibody: Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP therapeutic antibody

INN Name

Pelgifatamab

Target

FOLH1

Format

Whole mAb ADC

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2020

Companies

Bayer

Conditions Approved

NA

Conditions Active

Prostate cancer,Metastatic cancers

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

FOLH1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide